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Background. Increasing evidence supports a critical role of CD8+ T-cell immunity against influenza. Activation of mucosal 
CD8+ T cells, particularly tissue-resident memory T (TRM) cells recognizing conserved epitopes would mediate rapid and broad pro-
tection. Matrix protein 1 (M1) is a well-conserved internal protein. 
Methods. We studied the capacity of modified vaccinia Ankara (MVA)–vectored vaccine expressing nucleoprotein (NP) and 
M1 (MVA-NP+M1) to activate M1-specific CD8+ T-cell response, including TRM cells, in nasopharynx-associated lymphoid tissue 
from children and adults. 
Results. After MVA-NP+M1 stimulation, M1 was abundantly expressed in adenotonsillar epithelial cells and B cells. MVA-
NP+M1 activated a marked interferon γ–secreting T-cell response to M1 peptides. Using tetramer staining, we showed the vaccine 
activated a marked increase in M158–66 peptide-specific CD8
+ T cells in tonsillar mononuclear cells of HLA-matched individuals. 
We also demonstrated MVA-NP+M1 activated a substantial increase in TRM cells exhibiting effector memory T-cell phenotype. On 
recall antigen recognition, M1-specific T cells rapidly undergo cytotoxic degranulation, release granzyme B and proinflammatory 
cytokines, leading to target cell killing. 
Conclusions.  MVA-NP+M1 elicits a substantial M1-specific T-cell response, including TRM cells, in nasopharynx-associated 
lymphoid tissue, demonstrating its strong capacity to expand memory T-cell pool exhibiting effector memory T-cell phenotype, 
therefore offering great potential for rapid and broad protection against influenza reinfection.
Keywords. Influenza; T -ell immunity; vaccine; antigen-specific T cell; tissue-resident memory T cells (TRM); nasopharynx-
associated lymphoid tissue; cytotoxic T cell.
Influenza still causes widespread morbidity and mortality, 
despite the available vaccines. Current influenza vaccines 
predominantly induce subtype-specific antibodies toward he-
magglutinin. Because hemagglutinin continuously mutates, 
vaccine composition needs to be updated every year, and vac-
cine efficacy varies considerably depending on how well the 
vaccine strains match circulating viruses [1]. There is a need 
for more effective vaccines that confer broad immunity against 
influenza, including those with potential to cause pandemics.
Although neutralizing hemagglutinin-specific antibodies are 
considered the major protective responses [2], increasing ev-
idence supports an important role for CD8+ T-cell–mediated 
immunity. In individuals experimentally infected with influ-
enza, virus-specific cytotoxic T-cell killing reduced virus shed-
ding in absence of specific antibodies [3]. Preexisting cytotoxic 
CD8+ T cells were associated with decreased disease severity in 
patients infected with pandemic H1N1 virus [4].
The majority of influenza virus-specific CD8+ T cells recog-
nize epitopes shared among virus subtypes, including internal 
antigens nucleoprotein (NP) and matrix protein 1 (M1) [5, 6], 
which are highly conserved with >90% homology among dif-
ferent strains [7]. M1 plays a pivotal role in influenza virus 
replication [8, 9]. Activation of these T-cell responses would 
mediate a broadly cross-reactive protection [10]. A number of 
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novel T-cell–based influenza vaccines are being developed [11], 
including modified vaccinia Ankara virus (MVA)–vectored 
vaccines [12–14]. MVA-vectored vaccine expressing NP and 
M1 (MVA-NP+M1) is one of the promising vaccine candidates, 
showing activation of antigen-specific T-cell responses in pe-
ripheral blood after parenteral immunization [15, 16].
Tissue-resident memory T (TRM) cells reside in tissues and 
provide rapid response against reinfections at body surfaces 
[17]. These cells are anatomically positioned to quickly respond 
to local infection. Animal models showed that TRM cells made 
critical contributions to protective immunity against local chal-
lenges and were much more effective than recirculating memory 
T cells [18–20]. A vaccine strategy that enables establishment 
and/or expands mucosal TRM cells would have enormous poten-
tial for immediate protection against reinfection, offering more 
effective disease control [21].
Because influenza virus infects through nasopharyngeal mu-
cosa, local intranasal vaccine delivery that activates cross-re-
active mucosal T-cell immunity, including TRM cells, offers an 
attractive strategy. Intranasal live attenuated influenza vaccine 
(LAIV) has been shown to induce local and systemic antibodies 
and T-cell immunity in children [22–24]. Aerosol delivery of a 
candidate universal influenza vaccine induced local cellular re-
sponses associated with partial protection against heterosubtypic 
influenza A in pigs [25]. Intranasal immunization relies on local 
nasopharynx-associated lymphoid tissue (NALT) to induce T- 
and B-cell responses. Adenotonsillar tissues are major compo-
nents of human NALT and are known to be important induction 
sites for immunity against respiratory pathogens [26–28].
It was previously demonstrated that cross-reactive memory 
B-cell responses were primed after 2009 pdmH1N1 infection 
[29] and activation of NP-specific T-cell response by MVA-
NP+M1 in human NALT [30]. Because M1 contains major 
immunodominant CD8+ T-cell epitopes and HLA-A2 is among 
the most common HLA alleles (20%–30%) [31], we examined 
HLA-A2 restricted M158–66  peptide-specific CD8
+ T-cell re-
sponses in adenotonsillar tissue after MVA-NP+M1 stimula-
tion. We showed that MVA-NP+M1 elicits marked increases 
in M1-specific CD8+ T cells, including TRM cells, which exhibit 
rapid degranulation and target cell killing on recall antigen 
recognition.
METHODS
Patients and Samples
Tonsillar tissues and peripheral blood samples were obtained 
from immunocompetent children and adults (aged 2–34 years) 
undergoing tonsillectomy owing to upper airway obstruc-
tion. Tissue samples were obtained from Alder Hey Children’s 
Hospital and Aintree University Hospital in Liverpool, United 
Kingdom. Demographic information for studied patients is 
summarized in Table 1. Patients who had any known immuno-
deficiency were excluded, as were those with grossly inflamed 
tonsillar tissues. Ethical approval was obtained (Reference 
no. 14/SS/1058), and informed consent was obtained in all cases.
Vaccines and Peptides
MVA-NP+M1 is MVA virus expressing NP and M1 from A/
Panama/2007/99, as a fusion protein joined by a 7–amino acid 
linker, from vaccinia p7.5 early/late promoter. Wild-type MVA 
was nonrecombinant MVA used as a vector control. Following 
the manufacturer’s instructions, 9-mer conserved peptides of 
influenza M1 (BEI resources) (Table 2) were reconstituted in 
50% acetonitrile or dimethyl sulfoxide; 10 or 11 peptides were 
pooled at a concentration of 0.1  mg/mL per peptide. M158–66 
(GILGFVFTL) (IBA) was reconstituted in dimethyl sulfoxide 
(50%) at a final concentration of 1 mg/mL.
Fluorescence-Labeled Antibodies and M1 Tetramer
Fluorescence-labeled antibodies were used in flow cytometry, 
including antibodies to HLA-A2, CD19, CD3, CD11c, CD123, 
CD8, CD69, granzyme B, CD107a, interferon (IFN) γ, tumor 
necrosis factor (TNF) α, interleukin 2 (IL-2), CD20, CD38, 
Table 1. Study Patients by Age
Patient Group Age, Mean (Range), y
Children  
 Group 1 (n = 6) 2.5 (2–3.5)
 Group 2 (n = 12) 5.7 (4–9)
Adults (n = 9) 20.6 (16–34)
Table 2. 9-Mer Peptides of Conserved Major Histocompatibility Complex 
Class I Binding Epitopes from Matrix Protein 1 of Influenza A Virusesa
Peptide No. by Pool Amino Acid Sequence HLA Restriction
Pool 1   
 1 29-EDVFAGKNT-37 HLA-A*03
 2 31-VFAGKNTDL-39 HLA-A*2402, HLA-B*08
 3 37-TDLEALMEW-45 HLA-A*01
 4 49-RPILSPLTK-57 HLA-A*03
 5 51-ILSPLTKGI-59 HLA-A*0201
 6 56-TKGILGFVF-64 HLA-A*02
 7 58-GILGFVFTL-66 HLA-A*02, HLA-A*2402
 8 60-LGFVFTLTV-68 HLA-A*02
 9 66-LTVPSERGL-74 HLA-A*02
 10 68-VPSERGLQR-76 HLA-A*02
Pool 2   
 11 71-ERGLQRRRF-79 HLA-A*02
 12 75-QRRRFVQNA-83 HLA-A*02
 13 76-RRRFVQNAL-84 HLA-A*02
 14 122-GALASCMGL-130 HLA-B*35
 15 123-ALASCMGLI-131 HLA-B*35
 16 124-LASCMGLIY-132 HLA-B*35
 17 126-SCMGLIYNR-134 HLA-B*35
 18 177-NRMVLASTT-185 HLA-A*0301, HLA-A*11
 19 179-MVLASTTAK-187 HLA-A*0301, HLA-A*11
 20 180-VLASTTAKA-188 HLA-A*0301, HLA-A*11
 21 181-LASTTAKAM-189 HLA-A*0301, HLA-A*11
aObtained from BEI Resources (NR-2667).
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CD27, immunoglobulin D (IgD), CCR7, CD45RA, and CD103 
(BD Bioscience or Biolegend). Anti-M1 antibody (abcam) 
was conjugated with phycoerythrin (PE) using LYNX conju-
gation (Bio-Rad) to measure M1 expression. HLA-A02*01–
GILGFVFTL (M158–66)–PE tetramer (MBL) (M1-Tm) was used 
for staining M1-specific CD8+ T cells.
Cell Isolation
Tonsillar mononuclear cells (MNCs) were isolated using den-
sity gradient centrifugation, as described elsewhere [32, 33]. 
Tonsillar MNCs were resuspended in Roswell Park Memorial 
Institute 1640 (RPMI 1640)  medium containing HEPES, 
L-glutamine, 10% heat-inactivated fetal bovine serum, 100 U/
mL penicillin and 100  μg/mL streptomycin (Gibco), termed 
“complete RPMI medium.” MNCs were screened for HLA-A2 
type by means of flow cytometry.
Measurement of M1 Expression in Tonsillar MNCs
Tonsillar MNCs were stimulated with MVA-NP+M1 at 1.0 
multiplicity of infection and incubated for 18–20 hours. 
MNCs were stained for epithelial cell markers, including 
pancytokeratin and epithelial cellular adhesion molecule, and 
CD19/CD4/CD11c/CD123, followed by intracellular staining 
(Suppl figure S1) for M1 expression, using anti-M1 antibody. 
B-cell subsets were determined by means of fluorescence 
staining and identified as memory (CD19+CD20+CD38−CD2
7+IgD−), naive (CD19+CD20+CD38−IgD+CD27−) and germinal 
center B cells (CD19+CD20+CD38+) [34].
Cell Stimulation for T-Cell Assays
Tonsillar MNCs were cocultured with either MVA-NP+M1 or 
wild-type MVA at 1 × 105 plaque-forming units/mL. Cell cul-
ture in complete RPMI medium was supplemented with 2% 
autologous human plasma. Tonsillar MNCs were incubated 
for 7  days before any further experiments. Non–HLA-typed 
tonsillar MNCs were used for pooled-peptide stimulation 
and IFN-γ enzyme-linked immunospot (ELISPOT) assay, and 
MNCs from HLA-A2+ individuals were used to determine 
M1-specific CD8+ T-cell response with tetramer staining.
IFN-γ ELISPOT Assay
At day 7 after culture, MVA-NP+M1-stimulated cells were 
rested in RPMI medium for 2  days, followed by IFN-γ 
ELISPOT assay (eBioscience). ELISPOT plates  (Millipore) 
were coated with anti-IFN-γ antibody overnight. Next, 2 × 
105 cells stimulated with M1 peptide pools (10  μg/mL per 
peptide) were seeded in plate wells. Cells without stimula-
tion were used as a negative control, and cells stimulated 
with SEB (BEI Resources) as a positive control. The plate was 
incubated for 24 hours, followed by addition of anti–IFN-γ 
detection antibody and avidin–horseradish peroxidase. 
Spots were developed by adding 3-amino-9-ethyl carbazole 
(Sigma) and counted using an EliSpot Reader.
Detection of M158–66-Specific CD8
+ T Cells and TRM Cells
For flow cytometric analysis of M1-Tm+ CD8+ T cells and 
their phenotypes in tonsillar tissue, freshly isolated tonsillar 
MNCs, or MNCs after coincubation with M158–66 peptide for 
2  days (to expand M1-Tm+ cells), were stained with HLA-
A02*01-M158–66-PE tetramer. HLA-A02*01 control tetramers 
including HLA-A02*01-HPV16 E7 (-YMLDLQPET) and 
HLA-A02*01–negative control tetramer (-ALAAAAAAV) 
(MBL) were used. The specific detection of M1-Tm+ cells in 
tonsillar MNCs was confirmed by positive staining in CD8+ T 
cells only by M1-Tm tetramer, and negative staining by con-
trol tetramers in MNCs after M1 peptide stimulation (data 
not shown). Tonsillar MNCs were also cocultured with MVA-
NP+M1, followed by analysis of M1-Tm+ cells. For detection 
of M1-specific TRM, in addition to the above, MNCs were 
costained with anti-CD103, anti-CD69, anti-CD45RA, and 
anti-CCR7 antibodies.
Measurement of T-Cell Proliferation
Tonsillar MNCs were labeled with carboxyfluorescein 
succinimidyl ester (CFSE; 5 μmol/L) (Invitrogen) [35]. CFSE-
labeled cells were resuspended in RPMI medium supplemented 
with 2% autologous human plasma before stimulation with 
1 × 105 plaque-forming units/mL of MVA-NP+M1 for 5 days. 
Cells were then stained for CD8 and M1-Tm, followed by flow 
cytometry.
Detection of CD107a Expression and Intracellular Cytokines
After 7-day MVA-NP+M1 stimulation, tonsillar MNCs were 
pulsed with 0.25  μg/mL M158–66 peptide and cocultured with 
anti-CD107a antibody in the presence of brefeldin A  and 
monensin (eBioscience). Cells were collected and stained for 
CD8 and M1-Tm and intracellular cytokines, followed by flow 
cytometry.
Cytotoxic Killing Assay
Isolated CD8+ T cells after MVA-NP+M1 stimulation were 
cocultured with M158–66-pulsed B cells, as described elsewhere 
[36]. Briefly, autologous B cells were isolated from cryopre-
served tonsillar MNCs and incubated overnight with 40 ng/mL 
recombinant IFN-γ (Peprotech). B cells were then labeled with 
either 0.02 μmol/L (Target cell-CFSElow [Tlow]) or 0.2 μmol/L 
(Target cell-CFSEhigh [Thigh]) CFSE for 15 minutes. Tlow cells 
were pulsed with 5 μg/mL M158–66 for 45 minutes. Both Tlow and 
Thigh cells were adjusted to 2 × 10
5 cells/mL and mixed at a 1:1 
ratio. For effector cells, isolated CD8+ T cells after stimulation 
were adjusted to a cell count of 4–10 × 106/mL before 2-fold 
serial dilutions were made (1:1 to 1:32). CD8+ T cells were 
then cocultured at different ratios with mixed Tlow and Thigh 
cells for 6 hours. Mixed Tlow and Thigh cells only (without CD8
+ 
T cells) were cultured as negative control. Cells were harvested 
and stained with LIVE/DEAD Far Red stain (Invitrogen) for 
30 minutes before staining for CD8 and M1-Tm.
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Flow Cytometry
Fluorescence-labeled cells were analyzed using a FACSCalibur 
cytometer with CellQuest v5.1  software or a FACSCelesta 
cytometer with FACSDiva v8.0.3 software (both BD) and ana-
lyzed using FlowJo 8.7 software.
Statistical Analysis
For 2-group comparisons, based on normality of data, para-
metric paired t test, nonparametric Wilcoxon matched-pairs 
signed rank test and nonparametric Mann-Whitney test were 
performed using GraphPad Prism. Differences were considered 
statistically significant at P < .05.
RESULTS
M1 Antigen Expression in NALT After MVA-NP+M1 Stimulation
To determine whether M1 antigen was expressed in tonsillar 
cells after MVA-NP+M1 stimulation, we used intracellular M1 
staining to examine M1 expression in tonsillar MNCs. As shown 
in Figure 1A and 1B, after stimulation, M1 was abundantly ex-
pressed in tonsillar epithelial cells (mean [standard error of 
the mean (SEM)], 34.5% [3.2%]) and B cells (35.2% [7.55%]), 
but only a small number of T cells (2.3% [0.6%]). Among B 
cells, M1 expression was detected in memory (mean [SEM], 
55.8% [2.2%]), naive (48.7% [2.5%]), and germinal center 
(22.7 [0.9%]) B cells, respectively (data not shown). Among 
tonsillar dendritic cells (DCs), M1 expression was shown in 
myeloid DCs (mean [SEM], 21.2% [3.2%]) and plasmacytoid 
DCs (22.0% [7.1%]) (Figure 1B). As a control, no M1 expres-
sion was detected in any cell types after stimulation by MVA 
vector alone. MVA-NP+M1 elicited mucosal M1-specific T-cell 
responses.
Having shown abundant M1 expression in tonsillar MNCs, 
we investigated whether MVA-NP+M1 activated M1-specific 
T-cell responses. After MVA-NP+M1 stimulation, tonsillar 
MNCs were coincubated with 9-mer M1 peptide pools (Table 
2), followed by IFN-γ ELISPOT assay. A  marked increase in 
IFN-γ–secreting cells was found in MNCs stimulated by MVA-
NP+M1, compared with those stimulated by MVA vector alone 
(Figure 1C and 1D; P  <  .05). Subsequent flow cytometry re-
vealed that the increase in IFN-γ–secreting cells after M1 pep-
tide restimulation was predominantly from CD8+ T cells and 
not from CD4+ T cells (Figure 1E), with a mean (SEM) increase 
of 0.27% (0.05%) of IFN-γ–secreting cells (percentage of CD8+ 
T cells). This suggests that MVA-NP+M1 stimulation activates 
a marked M1-specific T-cell response.
To confirm this, we examined the M1-specific CD8+ T-cell 
response, using HLA-A2–restricted M158–66-specific tetramer 
(Tm) staining in HLA-matched individuals (Figure 2A). 
Frequencies of M1-Tm+ cells in freshly isolated MNCs were gen-
erally low (median, 0.10%). MVA-NP+M1 stimulation elicited 
a marked increase in M1-Tm+ cells (median, 0.37%), compared 
with stimulation by MVA vector or medium control (Figure 2B; 
P  <  .001). When MVA-NP+M1-activated M1-Tm+ cell re-
sponse was compared among different age groups (Table 1), 
an age-dependent increase was shown in M1-Tm+ cell response. 
In general, children <4 years old showed a low or modest re-
sponse, and older children and adults demonstrated stronger 
responses (Figure 2C). Further analysis with CFSE cell tracing 
demonstrated that MVA-NP+M1 activated a proliferative 
M1-Tm+ cell response in tonsillar MNCs, compared with MVA 
vector only (Figure 2D; P < .05).
M1-Specific TRM Cell Response to MVA-NP+M1
To determine whether there were M1-specific TRM cells in NALT 
and whether MVA-NP+M1 activated an increase in TRM cells, 
we studied tonsillar MNCs from HLA-matched patients (aged 
5–24  years) by costaining TRM cell markers and M1 tetramer. 
Because frequencies of M1-Tm+ cells in ex vivo tonsillar tissue 
were low, we used M1-specific peptide to enrich M1-Tm+ cells 
in tonsillar MNCs (and in peripheral blood MNCs [PBMCs]) 
by coincubation with M158–66 peptide for 2 days. 
The phenotypes of expanded M1-Tm+ cells after pep-
tide stimulation showed no difference in freshly isolated 
MNCs (data not shown). In tonsillar MNCs, a mean (SEM) 
of 25.1% (3.2%) M1-Tm+ cells expressed CD103+, therefore 
identified as M1-specific TRM cells, and most of them were 
CD103+CD69+ TRM cells (Figure 3A and 3E). There was also 
a mean (SEM) of 38.1% (3.6%) of M1-Tm+ cells expressing 
CD69 but not CD103 (CD103−CD69+). Of M1-Tm+ cells in 
MNCs, about 64% were of effector memory T-cell pheno-
type (CD45RA−CCR7−) (Figure 3B and 3F). Among M1-Tm+ 
cell subsets, the majority (mean [SEM], 64.2% [8.4%]) of 
CD103+CD69+ TRM cells were of effector memory T-cell phe-
notype, compared with 42.6% (6.1%) and 14.4% (2.5%), re-
spectively, for CD103−CD69+ and CD103−CD69− subsets 
(Figure 3I). By contrast, in PBMCs from the same patients, 
no M1-Tm+ cells expressed CD103 (thus non-TRM cells), and 
only approximately 20% were of CD45RA−CCR7− effector 
memory phenotype, with the majority of CD45RA+CCR7− 
phenotype (Figure 3B and 3F).
After MVA-NP+M1 stimulation, there was a substan-
tial increase in M1-Tm+ cells (6–18-fold-increase), including 
both CD103+ and CD103− cell subsets, and a large majority 
(approximately 90%) expressed CD45RA−CCR7− phenotype 
(Figure 3C, 3G, and 3H). In CD103+ TRM cells, there was a 
marked increase in CD103+CD69− subset which accounted 
for approximately 75% of CD103+TRM cells, whereas approx-
imately 25% were CD103+CD69+ (Figure 3C and 3G). This 
contrasted with findings in freshly isolated MNCs or M1 pep-
tide–expanded MNCs, in which CD103+ cells were primarily 
CD103+CD69+. Furthermore, when the memory phenotypes 
were analyzed, more CD103+CD69− than CD103+CD69+ or 
CD103−CD69+ TRM cells exhibited an effector memory phe-
notype (CD45RA−CCR7−) (mean, 86.1% vs 65.6% and 42.2%, 
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Figure 1. Expression of matrix protein 1 (M1) in tonsillar mononuclear cells (MNCs) after stimulation with modified vaccinia Ankara (MVA)–vectored vaccine expressing 
nucleoprotein (NP) and M1 (MVA-NP+M1), and T-cell responses to conserved M1 peptides. M1 expression was examined in tonsillar MNCs after either MVA-NP+M1 or 
wild-type MVA (MVA-wt) stimulation for 18 hours. A, Representative flow cytometric histograms showed the expression of M1 in tonsillar epithelial cells and B cells after 
stimulation by MVA-NP+M1 (red line) compared with MVA-wt (black line). B, Bar charts show the percentages of M1 expression in epithelial cells, B cells, plasmacytoid den-
dritic cells (pDCs), myeloid dendritic cells (mDCs), and T cells after MVA-NP+M1 stimulation, compared with MVA-wt stimulation (n = 3; values represent means with standard 
errors of the mean). C, After MVA-NP+M1 stimulation and cell resting, the frequency of interferon (IFN) γ–secreting T cells on restimulation by conserved M1 peptide pools 
were determined by means of IFN-γ enzyme-linked immunospot assay. Representative images showed spots (IFN-γ–secreting cells) in MNCs stimulated by MVA-NP+M1-
versus MVA-wt, before and after restimulation by M1 peptide pools. D, IFN-γ spot-forming cell (SFC) counts in MNCs stimulated by MVA-NP+M1 or MVA-wt-stimulated 
MNCs followed by M1 peptide pool stimulation (n = 7). *P < .05, Wilcoxon signed rank test). SFC counts were obtained by subtracting background SFC count in cells without 
peptide restimulation. E, Representative dot plots showed a higher frequency of IFN-γ–producing CD8+ T cells than CD4+ T cells after restimulation by M1 peptide pools in 
MVA-NP+M1-stimulated MNCs (1 of 3 representative samples shown).
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Figure 2. M158–66 peptide-specific CD8
+ T cells activated by modified vaccinia Ankara (MVA)–vectored vaccine expressing nucleoprotein (NP) and matrix protein 1 
(M1) (MVA-NP+M1). M158–66 peptide-specific CD8
+ T cells (M1-Tm+) were identified using M1 tetramer staining in HLA-A2+ patients after 7-day culture of tonsillar 
mononuclear cells (MNCs) with MVA-NP+M1, wild-type MVA (MVA-wt), or medium control. A, Gating strategy for analysis of M1-Tm+ cells. B, MVA-NP+M1 activated 
an increase in M1-Tm+ compared with MVA-wt cells in children (green circle <4 years, blue >4 years) and adults (red circle) (n = 27). ‡P < .001; NS, not significant 
(Wilcoxon signed rank test). C, Frequency of M1-Tm+ cells among different age groups (displayed as medians with interquartile ranges). *P < .05; †P < .01. D, Gating 
on M1-Tm+ cells. Representative histogram shows that M1-Tm+ cell proliferation was activated by MVA-NP+M1 (blue line), compared with MVA-wt control (gray 
shading). E, Proliferation of M1-Tm+ cells (0.02 μmol/L [Tlow]) after stimulation of tonsillar MNCs by MVA-NP+M1, compared with MVA-wt control (n = 3). *P <  .05 
(Wilcoxon signed rank test).
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Figure 3. Matrix protein 1 (M1)–specific tissue-resident memory T (TRM)–cell response in tonsillar mononuclear cells (MNCs) activated by modified vaccinia Ankara (MVA)–vec-
tored vaccine expressing nucleoprotein (NP) and M1 (MVA-NP+M1). A, C, Representative dot plots (gated on M1-Tm+ CD8+ T cells only) demonstrated the presence of preexisting 
M158–66 peptide-specific TRM cells (CD103
+CD69+) in M1 peptide–expanded tonsillar MNCs and peripheral blood MNCs (PBMCs) (A) and substantially increased numbers of both CD103+ 
and CD103− M1-Tm+ (M1-tetramer) cells after MVA-NP+M1 stimulation at day 7, particularly the increase in CD103+CD69− subset in tonsillar MNCs (C). A, C, E, G, This contrasted with 
the findings in PBMCs showing the absence of CD103+CD69+ TRM cells in both M1 peptide–expanded (A, E) and MVA-NP+M1-stimulated PBMCs (C, G). B, D, F, H, Memory phenotypes of 
M1-Tm+ cells were examined using CCR7 and CD45RA markers in tonsillar MNCs compared with PBMCs (M1 peptide–expanded [B, F] and MVA-NP+M1 stimulated [D, H]). E–H, TRM and 
non-TRM cell subsets (E, G) and their memory phenotypes (F, H) of M1-Tm
+ cells in tonsillar MNCs and PBMCs after M1 peptide and MVA-NP+M1 stimulation. I, J, M1-Tm+ cell memory 
phenotypes in different TRM and non-TRM cell subsets in tonsillar MNCs after M1 peptide (I) or MVA-NP+M1 stimulation (J). *P < .05; †P < .01 (comparison with CD103
−CD69− non-TRM 
cells; n = 5).
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respectively) (Figure 3J). When PBMCs from the same patients 
were analyzed, a marked increase in M1-Tm+ cells was also 
seen, but these cells in PBMCs were largely CD103−CD69− non-
TRM cells (Figure 3C and 3G).
Cytotoxic Functions and Killing Property of MVA-NP+M1-Activated 
M1-Specific CD8+ T Cells
To determine whether MVA-NP+M1-activated M1-specific 
CD8+ T cells in tonsillar MNCs were functionally active, we 
examined the expression of cytotoxic molecules and cytokines 
in M1-Tm+ cells. At day 7 after vaccine stimulation, the M1-Tm+ 
cells expressed a high level of granzyme B (Figure 4A and 4B). 
Tonsillar MNCs were subsequently pulsed with M158–66 peptide, 
followed by detection of surface CD107a (marker for degran-
ulation) and cytokine expression. Both CD107a expression 
and IFN-γ expression were markedly up-regulated in M1-Tm+ 
cells after M158–66 peptide pulsing (Figure 4C). The kinetics of 
CD107a and IFN-γ expression were further studied and a sim-
ilar pattern was shown for both (Figure 4D and 4E). Notably, 
the up-regulation in expression was more rapid in CD107a than 
in IFN-γ. 
At 1 hour after peptide pulsing, approximately 40% of M1-Tm+ 
cells expressed CD107a, compared with 10% producing IFN-γ 
(P < .05). Both surface CD107a expression and IFN-γ produc-
tion seemed to peak after 3 hours (Figure 4D and 4E). IFN-γ 
and TNF-α were abundantly expressed in M1-Tm+ cells after 
peptide pulsing (Figure 4F and 4G). Figure 4H shows the fre-
quencies of M1-Tm+ cells expressing different cytokine profiles, 
with the most frequently detected M1-Tm+ cells coexpressing 
CD107a with IFN-γ and TNF-α (45%). Some M1-Tm+ cells 
(3%) were shown to coexpress CD107a and 3 cytokines, IFN-γ, 
TNF-α, and IL-2 (Figure 4H).
We further investigated whether M1-Tm+ cells were capable 
of the cytotoxic killing of target cells. After MVA-NP+M1 
stimulation, isolated CD8+ T cells (as effector T cells) were 
cocultured with M158–66 peptide-pulsed target B cells, followed 
by flow cytometric measurement of target cell lysis. As demon-
strated in Figure 5A, there was a marked decrease in peptide-
pulsed target B cells (Tlow) but no decrease in B cells without 
peptide-pulsing (Thigh) after coculture with effector T cells, 
indicating M1-specific target cell lysis. In all 3 samples tested, 
the increase in target cell lysis was correlated well with the 
increase in effector-target cell ratio (Figure 5B).
DISCUSSION
Because intranasal vaccination is considered an effective vac-
cination strategy against respiratory pathogens [22–24], we 
investigated the potential of MVA-NP+M1 as a mucosal vac-
cine to activate anti-influenza T-cell responses in human NALT. 
We demonstrated that MVA-NP+M1 activates a prominent 
M1-specific cytotoxic T-cell response with a marked increase in 
M1-specific TRM cells.
After MVA-NP+M1 stimulation, we showed that M1 antigen 
was highly expressed in both tonsillar epithelial cells and B cells. 
This suggest that MVA-NP+M1 has the capacity to efficiently 
infect tonsillar cryptal epithelium and present M1 antigen. 
Tonsillar tissue has a reticular crypt epithelium containing both 
epithelial and nonepithelial immune cells. Efficient infection of 
epithelium by MVA-vectored vaccine would provide a favor-
able environment for vaccine uptake and antigen presentation. 
Memory B cells, representing a major nonepithelial immune cell 
subset, were found mainly within intraepithelial areas and have 
a strong capacity to present antigen directly to T cells, owing to 
the constitutive expression of costimulatory molecules [37–39]. 
The unique anatomic localization of memory B cells 
in intraepithelial areas, together with the strong antigen-
presenting capacity, has been considered critical for prompt and 
robust memory antibody responses [37]. It is therefore possible 
that memory B cells are infected by the MVA vaccine virus and 
efficiently present the vaccine antigen (eg, M1) to memory T 
cells, contributing to activation of memory T cells in tonsillar 
MNCs. DCs may also contribute to vaccine uptake and antigen 
processing, because significant proportions of myeloid and 
plasmacytoid DCs showed M1 expression, consistent with pre-
vious findings [40].
With IFN-γ ELISPOT assay, we demonstrated that MVA-
NP+M1 activated a marked increase in IFN-γ–secreting CD8+ 
T cells specific to conserved M1 epitopes. Furthermore, using 
M158–66-specific tetramer staining, we showed that MVA-
NP+M1 stimulation elicited a marked increase in M1-Tm+ T 
cells in tonsillar MNCs from HLA-matched individuals, partic-
ularly in older children and adults. M158–66-specific CD8
+ T cells 
have been shown to protect against influenza infection in HLA-
A2 transgenic mice [41]. Our results therefore provide evidence 
supporting the capacity of MVA-NP+M1 to elicit M1-specific 
CD8+ T-cell responses with the potential for protection against 
influenza in the human nasopharynx.
Recent research supports a critical role of TRM cells in pro-
viding a rapid protection against influenza. TRM cells in 
human lungs were shown to mount a rapid response and kill 
influenza-infected epithelial cells and contribute to protection 
[42, 43]. Using M1 tetramer and CD103/CD69 costaining, we 
demonstrated the presence of CD103+ M1-specific CD8+ TRM 
cells in tonsillar tissue, which were expanded by M1-specific 
peptide. M1-Tm+ cells included were both CD103+CD69+ 
and CD103−CD69+ TRM subsets. Similar to findings of a pre-
vious study on EBV-specific TRM cells in tonsillar tissue [44], 
M1-specific CD103+ cells were largely restricted to CD69+ cells, 
and a large proportion of these TRM cells were of effector memory 
T-cell phenotype. It has been shown that CD103+CD69+ TRM 
cells preferentially localized to tonsillar epithelial surface, 
whereas CD103−CD69+ cells largely localized in extrafolicular 
regions [44]. Our results therefore support the presence of 
M1-specific TRM cells in tonsillar epithelium, derived from 
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Figure 4. Cytotoxic molecule and proinflammatory cytokine expression profiles of matrix protein 1 (M1)–specific CD8+ T cells. Tonsillar mononuclear cells (MNCs) 
were stimulated by modified vaccinia Ankara (MVA)–vectored vaccine expressing nucleoprotein (NP) and M1 (MVA-NP+M1) for 7 days, followed by detection of M1-Tm+ 
(M1-tetramer) cells and expression of cytotoxic molecules. Tonsillar MNCs were subsequently pulsed with M158–66 peptide for 6 hours, followed by detection of surface 
CD107a and intracellular cytokines. A, B, MVA-NP+M1-activated M1-Tm+ cells expressing high level of granzyme B, compared with wild-type MVA (MVA-wt) alone. A, 
Representative plots. B, Expression in 8 samples. *P < .05). C, After M1 peptide pulsing, both surface CD107a and intracellular interferon (IFN) γ were highly expressed in 
M1-Tm+ cells, compared with the low level in M1-Tm− cells (n = 8 and n = 13 respectively). ‡P < .001). D, E, Representative dot plots (D) and kinetics curves (E) showed the 
coexpression of surface CD107a and intracellular IFN-γ in M1-Tm+ cells after peptide pulsing. At 1 hour, the percentages of CD107a+ cells were significantly higher than 
those of IFN-γ + cells (n = 4); mean and standard error of the mean are shown at each time point. *P < .05 (paired t test). F, G, Representative dot plots showed the high level 
of expression of IFN-γ (F) and tumor necrosis factor (TNF) α (G) in MVA-NP+M1-activated M1-Tm+ cells. H, Pie and bar charts demonstrate functional profile of M1-Tm+ cells 
in MVA-NP+M1-activated tonsillar MNCs followed by 6-hour restimulation with an M158–66 peptide, showing coexpression of CD107a and 3 cytokines, IFN-γ, TNF-α, and 
interleukin 2 (IL-2) (1 of 2 representative samples is shown).
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memory T cells primed by previous influenza infection. These 
cells largely exhibit effector memory T-cell phenotype, with the 
ability to mount a fast response to reinfection.
After MNA-NP+M1 stimulation, there was an increase in 
M1-specific TRM cells (CD103
+) and non-TRM cells (CD103
−) 
in tonsillar MNCs. Interestingly, of CD103+ TRM cells, the ma-
jority were CD103+CD69−, whereas only approximately 25% 
were CD103+CD69+, cells which were predominant in unstimu-
lated tonsillar MNCs. It would be interesting to know whether 
there is any functional difference between CD103+CD69− and 
CD103+CD69+ subsets in future studies. The fact that a large 
majority of CD103+CD69− cells exhibited effector memory 
T-cell phenotype indicates they have the capacity to respond to 
reinfection rapidly. 
These results suggest that MVA-NP+M1, if used as an 
intranasal vaccine, could elicit a proliferative response of TRM 
cells, to expand the TRM memory T-cell pool in NALT and 
offer rapid protection against influenza infection in the naso-
pharynx. MVA-NP+M1 most likely acts by boosting preexisting 
memory CD8+ T cells, but not by inducing de novo M1-specific 
T cells, because tonsillar MNCs depleted of memory T cells 
(CD45RO+) failed to show any M1-Tm+ cells after MVA-
NP+M1 stimulation (data not shown).As a comparison, we also 
analyzed M1-Tm+ T cells in PBMCs, and we demonstrated the 
absence of TRM (CD103
+CD69+) cells in PBMCs before and after 
the vaccine stimulation. This supports the concept that CD103+ 
TRM cells are retained in peripheral tissue but not present in the 
circulation. Local mucosal vaccination may therefore offer dis-
tinctive advantage in expanding antigen-specific TRM cells in 
local tissues for rapid protection.
It is generally thought that cytotoxic CD8+ T cells exert their 
effector activities to limit virus infection and disease severity 
[6, 10] through degranulation, cytotoxic molecule release, and 
proinflammatory cytokines [45]. In the current study, we dem-
onstrated that M1-Tm+ cells activated by MVA-NP+M1 ex-
pressed a high level of granzyme B, which was subsequently 
released on recognition of M158–66 peptide, along with rapid 
up-regulation of surface CD107a expression. In addition, many 
M1-Tm+ cells coexpressed CD107a with IFN-γ and TNF-α, sug-
gesting that they produce both cytotoxic effector molecules and 
inflammatory cytokines on antigen-specific recognition. IFN-γ 
and TNF-α are potent proinflammatory cytokines and impor-
tant in antiviral activity. In addition to these 2 cytokines, some 
of these cells also coexpressed IL-2, which may exhibit more 
potent cytotoxic functions [46, 47]. Although CD4+ cells, rather 
than CD8+ T cells, are the main source of IL-2, a small number 
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Figure 5. Specific killing capacity of M158–66 peptide-specific CD8
+ T cells. Isolated CD8+ T cells after stimulation by modified vaccinia Ankara (MVA)–vectored vaccine 
expressing nucleoprotein (NP) and matrix protein 1 (M1) (MVA-NP+M1) were cocultured at different ratios with autologous B cells labeled with low (Tlow) and high (Thigh) with 
carboxyfluorescein succinimidyl ester (CFSE) intensities. Tlow cells were either pulsed with M158–66 peptide or were without pulsing, and Thigh cells were without pulsing. A, 
Representative dot plots and histogram demonstrating the decrease in target cells (Tlow) after M1 peptide pulsing (green gate or middle peak), compared with nonpulsing 
controls (gray shading), indicating M1-specific target cell killing. B, Correlations between percentages of M1-specific target cell lysis and effector-target (E/T) cell ratio in 3 
patients. E refers to effector number of M1-Tm+ (M1-tetramer) cells of isolated CD8+ T cells, and T to number of target Tlow cells. The proportion of M1-Tm
+ cells in the total 
isolated CD8+ T cells ranged from 1% to 4%.
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of CD8+ T cells can secrete IL-2 after receiving costimulatory 
signals, providing proliferation and survival signals to them-
selves or other cytotoxic T cells [45].
The kinetics of CD107a expression correlated well with 
that of cytokine (IFN-γ) production in the M1-Tm+ cells. The 
rapid up-regulation of surface CD107a expression (ie, degran-
ulation) in M1-Tm+ cells on specific antigen recognition sug-
gests that these M1-specific CD8+ T cells, including TRM cells, 
may mount an immediate cytotoxic response against influenza. 
Finally, using M1-specific peptide pulsed tonsillar B lympho-
cytes as target cells for the effector T-cell function, we showed 
thatMVA-NP+M1-activated M1-Tm+ cells had marked cyto-
toxic killing activity capable of target cell lysis.
In conclusion, we demonstrate that MVA-NP+M1 activated 
an M1-specific mucosal CD8+ T-cell response, including a sub-
stantial increase in TRM cells. These M1-specific T cells were pre-
dominantly of effector memory T-cell phenotype, exhibiting a 
high level of cytotoxic markers and producing proinflammatory 
cytokines, leading to specific killing of target cells on antigen 
recognition. Our results suggest that this novel vaccine expands 
the M1-specific TRM cell pool and activates cytotoxic T-cell 
responses to the conserved antigen, therefore offering great 
potential as an effective mucosal vaccine for fast and broad pro-
tection against reinfection of influenza virus in humans.
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